ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
SARS signature for Covid-19.pdf (600.27 kB)
0/0

Using the SARS Infection Transcriptional Signature to Identify Potential Treatments for Covid-19

preprint
submitted on 19.05.2020 and posted on 20.05.2020 by Richard Killick, Clive Ballard, Patrick Doherty, Gareth Williams
Gene expression data associated with viral infection of human cell lines is harnessed to define a conserved viral response signature. Drugs that tend to drive gene expression in the direction of the cellular viral response are significantly enriched for those with established antiviral activity. Transcription therefore facilitates a simple and effective filtering of candidate drugs to be put forward for bioassay validation.

History

Email Address of Submitting Author

gareth.2.williams@kcl.ac.uk

Institution

King's College London

Country

United Kingdom

ORCID For Submitting Author

0000-0001-9205-4943

Declaration of Conflict of Interest

CB reports grants and personal fees from Lundbeck and Acadia, and personal fees from Roche, Orion, GSK, Otusaka, Heptares, and Lilly outside the submitted work. GW, AG, EC, JC, DC and PD declare no conflicting interests.

Exports

Logo branding

Exports